Recurrent Osteosarcoma Completed Phase 1 Trials for Temozolomide (DB00853)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00077454Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsTreatment